

Supplementary Figures




Fig. S1. Maintenance of CHR with/without prior hydroxyurea use (intention-to-treat population, local laboratory data)
CHR, complete hematologic response; HU, hydroxyurea;
RR, relative risk




Fig. S2. Maintenance of CHR by age (intention-to-treat population, central laboratory data)

CHR, complete hematologic response; RR, relative risk




Fig. S3. Monthly mean hematocrit (A), platelets (B), and white blood cells (C) (intention-to-treat population, central laboratory data)
The horizontal dashed line represents the target value. Data are mean $\pm$ standard deviation




Fig. S4. Mean monthly drug exposure (safety population)




Fig. S5. *JAK2* V617F allele burden for individual patients (A) Data from patients who achieved an allele burden of $\leq 10\%$ at 36 months, $n = 9$, and (B) patients with an allele burden of $> 10\%$ at 36 months, $n = 17$. Data from week 148 or week 160 are shown as 36 months.